Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 15, 2007. The report serves as a notification of a major interest in GSK ordinary shares received from Legal & General Group Plc (L&G) on June 14, 2007, pursuant to Disclosure and Transparency Rules (DTR) 5.8.12.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory notification regarding shareholding thresholds rather than a financial performance report.
Material Changes
The material change reported is an increase in the voting rights held by Legal & General Group Plc (L&G) and its controlled undertakings:
- Previous Holding: Between 3% and 4% of voting rights.
- Current Holding: 4.00% of voting rights.
- Share Count: Increased from 218,457,607 shares to 228,794,061 shares.
- Transaction Date: June 13, 2007.
- Notification Date: June 14, 2007.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors related to GSK's operations. The document strictly details the chain of controlled undertakings through which L&G holds voting rights, including Legal & General Assurance (Pensions Management) Limited (PMC) and Legal & General Investment Management Limited (LGIM).
Investor Verification Checklist
- Verify the total number of voting rights outstanding (stated as 5,706,694,635) to confirm the 4.00% calculation.
- Confirm the breakdown of direct versus indirect holdings within the Legal & General Group structure.
- Check subsequent filings to determine if L&G crosses the 5% threshold, which may trigger additional disclosure requirements.
- Review GSK's concurrent financial reports (e.g., Form 20-F or interim results) for operational performance data not included in this 6-K.